Biomarkers in Breast Cancer: An Old Story with a New End

被引:45
作者
Alves, Lyvia Neves Rebello [1 ,2 ]
Meira, Debora Dummer [1 ,2 ]
Merigueti, Luiza Poppe [1 ]
Casotti, Matheus Correia [1 ,2 ]
Ventorim, Diego do Prado [3 ]
Almeida, Jucimara Ferreira Figueiredo [1 ]
de Sousa, Valdemir Pereira [1 ,2 ]
Sant'Ana, Marllon Cindra [1 ]
da Cruz, Rahna Goncalves Coutinho [1 ]
Louro, Luana Santos [4 ]
Santana, Gabriel Mendonca [4 ]
Louro, Thomas Erik Santos [5 ]
Salazar, Rhana Evangelista [1 ,2 ]
da Silva, Danielle Ribeiro Campos [1 ,2 ]
Zetum, Alexia Stefani Siqueira [1 ,2 ]
Trabach, Raquel Silva dos Reis [1 ]
Errera, Flavia Imbroisi Valle [1 ,2 ]
de Paula, Flavia [1 ,2 ]
dos Santos, Eldamaria de Vargas Wolfgramm [1 ,2 ]
de Carvalho, Elizeu Fagunde [6 ]
Louro, Iuri Drumond [1 ,2 ]
机构
[1] Univ Fed Espirito Santo UFES, Dept Ciencias Biol, Nucl Genet Humana & Mol, BR-29075910 Vitoria, ES, Brazil
[2] Univ Fed Espirito Santo, Programa Posgrad Biotecnol, BR-29047105 Vitoria, ES, Brazil
[3] Inst Fed Educ Ciencia & Tecnol Espirito Santo Ifes, BR-29150410 Cariacica, ES, Brazil
[4] Univ Fed Espirito Santo UFES, Ctr Ciencias Saude, Curso Med, BR-29090040 Vitoria, ES, Brazil
[5] Escola Super Ciencias Santa Casa Misericordia Vito, BR-29027502 Vitoria, ES, Brazil
[6] Univ Estado Rio de Janeiro UERJ, Inst Biol Roberto Alcantara Gomes IBRAG, BR-20551030 Rio de Janeiro, RJ, Brazil
关键词
breast cancer; cancer genetics; biomarkers; personalized medicine; EXTENDED ADJUVANT THERAPY; SINGLE-CELL; MAGNETIC-RESONANCE; TUMOR SIZE; TREATMENT DECISIONS; ENDOCRINE THERAPY; HISTOLOGIC GRADE; PREOPERATIVE ASSESSMENT; PROGESTERONE-RECEPTOR; DISTANT RECURRENCE;
D O I
10.3390/genes14071364
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Breast cancer is the second most frequent cancer in the world. It is a heterogeneous disease and the leading cause of cancer mortality in women. Advances in molecular technologies allowed for the identification of new and more specifics biomarkers for breast cancer diagnosis, prognosis, and risk prediction, enabling personalized treatments, improving therapy, and preventing overtreatment, undertreatment, and incorrect treatment. Several breast cancer biomarkers have been identified and, along with traditional biomarkers, they can assist physicians throughout treatment plan and increase therapy success. Despite the need of more data to improve specificity and determine the real clinical utility of some biomarkers, others are already established and can be used as a guide to make treatment decisions. In this review, we summarize the available traditional, novel, and potential biomarkers while also including gene expression profiles, breast cancer single-cell and polyploid giant cancer cells. We hope to help physicians understand tumor specific characteristics and support decision-making in patient-personalized clinical management, consequently improving treatment outcome.
引用
收藏
页数:29
相关论文
共 237 条
[1]   Prediction of adjuvant chemotherapy benefit in endocrine responsive, early breast cancer using multigene assays [J].
Albain, Kathy S. ;
Paik, Soonmyung ;
van't Veer, Laura .
BREAST, 2009, 18 :S141-S145
[2]  
Anatskaya OV, 2021, MOL BIOL+, V55, P813, DOI [10.1134/S0026893321050022, 10.31857/S0026898421060021]
[3]   Polyploidy and Myc Proto-Oncogenes Promote Stress Adaptation via Epigenetic Plasticity and Gene Regulatory Network Rewiring [J].
Anatskaya, Olga, V ;
Vinogradov, Alexander E. .
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (17)
[4]   Polyploidy as a Fundamental Phenomenon in Evolution, Development, Adaptation and Diseases [J].
Anatskaya, Olga, V ;
Vinogradov, Alexander E. .
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (07)
[5]   A Systematic Review of the Prevalence and Diagnostic Workup of PIK3CA Mutations in HR+/HER2-Metastatic Breast Cancer [J].
Anderson, Elizabeth J. ;
Mollon, Lea E. ;
Dean, Joni L. ;
Warholak, Terri L. ;
Aizer, Ayal ;
Platt, Emma A. ;
Tang, Derek H. ;
Davis, Lisa E. .
INTERNATIONAL JOURNAL OF BREAST CANCER, 2020, 2020
[6]   Cross-sectional imaging to evaluate the extent of regional nodal disease in breast cancer patients undergoing neoadjuvant systemic therapy [J].
Anderson, Tara L. ;
Glazebrook, Katrina N. ;
Murphy, Brittany L. ;
Viers, Lyndsay D. ;
Hieken, Tina J. .
EUROPEAN JOURNAL OF RADIOLOGY, 2017, 89 :163-168
[7]   Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2enegative advanced breast cancer: final overall survival results from SOLAR-1 [J].
Andre, F. ;
Ciruelos, E. M. ;
Juric, D. ;
Loibl, S. ;
Campone, M. ;
Mayer, I. A. ;
Rubovszky, G. ;
Yamashita, T. ;
Kaufman, B. ;
Lu, Y-S ;
Inoue, K. ;
Papai, Z. ;
Takahashi, M. ;
Ghaznawi, F. ;
Mills, D. ;
Kaper, M. ;
Miller, M. ;
Conte, P. F. ;
Iwata, H. ;
Rugo, H. S. .
ANNALS OF ONCOLOGY, 2021, 32 (02) :208-217
[8]   Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer: ASCO Guideline Update [J].
Andre, Fabrice ;
Ismaila, Nofisat ;
Allison, Kimberly H. ;
Barlow, William E. ;
Collyar, Deborah E. ;
Damodaran, Senthil ;
Henry, N. Lynn ;
Jhaveri, Komal ;
Kalinsky, Kevin ;
Kuderer, Nicole M. ;
Litvak, Anya ;
Mayer, Erica L. ;
Pusztai, Lajos ;
Raab, Rachel ;
Wolff, Antonio C. ;
Stearns, Vered .
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) :1816-+
[9]  
[Anonymous], NCCN CLIN PRACTICE G
[10]   Prognostic Significance of CHEK2 Mutation in Progression of Breast Cancer [J].
Ansari, Narges ;
Shahrabi, Saeid ;
Khosravi, Abbas ;
Shirzad, Reza ;
Rezaeean, Hadi .
LABORATORY MEDICINE, 2019, 50 (03) :E36-E41